Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hyphens Pharma International Total Current Liabilities Chart
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.
Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.
What does a Total Current Liabilities of S$49.1 Mil mean?
Hyphens Pharma International (SGX:1J5) has a Total Current Liabilities of S$49.1 Mil as of Jun. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Hyphens Pharma International and its competitors.
Is Hyphens Pharma International's Total Current Liabilities too high?
Hyphens Pharma International's current Total Current Liabilities is S$49.1 Mil. Overall, Hyphens Pharma International has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hyphens Pharma International's Total Current Liabilities compare to MCK and COR?
Hyphens Pharma International's Total Current Liabilities of S$49.1 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Medical Distribution company?
A good Total Current Liabilities depends on the Medical Distribution industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Hyphens Pharma International and its competitors. Hyphens Pharma International's current Total Current Liabilities is S$49.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hyphens Pharma International stock overvalued right now?
Based on GuruFocus' analysis, Hyphens Pharma International (SGX:1J5) is currently considered Modestly Overvalued. The stock's GF Value™ is S$0.31, compared to a current price of S$0.36 — trading 16.1% above its estimated fair value. The current Total Current Liabilities is S$49.1 Mil. Hyphens Pharma International's overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Hyphens Pharma International (SGX:1J5), the current Total Current Liabilities is S$49.1 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hyphens Pharma International (SGX:1J5) Overvalued in 2026?
Based on GuruFocus' analysis, Hyphens Pharma International stock appears to be overvalued.
The current stock price of S$0.36 is trading 16.1% above its estimated GF Value™ of S$0.31.
GuruFocus considers Hyphens Pharma International to be Modestly Overvalued.
Key valuation signals for SGX:1J5:
Total Current Liabilities: S$49.1 Mil
GF Value™: S$0.31 vs. price of S$0.36 (16.1% above fair value)
No single metric tells the full story. See the SGX:1J5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hyphens Pharma International Ltd is a pharmaceutical company. Its segments include the Pharmaceutical and Medical Aesthetics segment; Proprietary Brands segment; and Digital Platform and E-Pharmacy segment. The Pharmaceutical and Medical Aesthetics segment engages in the business of marketing and selling a range of pharmaceutical and medical aesthetics products with exclusivity in the relevant ASEAN countries. The Proprietary Brands segment develops, markets, and sells dermatological, pharmaceuticals and health supplement products. The Digital Platform and E-Pharmacy segment is a digital platform servicing procurement needs of healthcare professionals, healthcare institutions, and retail pharmacies, mainly in Singapore.
82GF Score
Get the complete analysis for SGX:1J5
Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:1J5 has been successfully added to your 
